SAN DIEGO, June 01, 2020 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological research, announced today that its subsidiary Sapphire Biotech, Inc. (“Sapphire”) has started pre-clinical animal drug studies on its new compound, SPX-1009.
SAN DIEGO, Feb. 10, 2020 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and cannabinoid research, announced today that its acquiree Sapphire Biotech, Inc. (“Sapphire”) has signed a Sponsored Research Agreement (“SRA”) with Arizona State University (“ASU”) to conduct preclinical studies using Quiescin Sulfhydryl Oxidase 1 (“QSOX1”) inhibitors as anti-neoplastic compounds.
SAN DIEGO, Feb. 10, 2020 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and cannabinoid research, announced today that its acquiree Sapphire Biotech, Inc. (“Sapphire”) has signed a Sponsored Research Agreement (“SRA”) with Arizona State University (“ASU”) to conduct preclinical studies using Quiescin Sulfhydryl Oxidase 1 (“QSOX1”) inhibitors as anti-neoplastic compounds.